Related references
Note: Only part of the references are listed.Cost-Benefit Analysis and the environment: The time horizon is of the essence
Tadhg O'Mahony
ENVIRONMENTAL IMPACT ASSESSMENT REVIEW (2021)
Parkinson's disease
Bastiaan R. Bloem et al.
LANCET (2021)
The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on 'Off'-time in Patients with Advanced Parkinson's Disease: A Systematic Review
Angelo Antonini et al.
ADVANCES IN THERAPY (2021)
A method for measuring time spent in bradykinesia and dyskinesia in people with Parkinson's disease using an ambulatory monitor
Hamid Khodakarami et al.
JOURNAL OF NEUROENGINEERING AND REHABILITATION (2021)
Therapeutic Strategies to Treat or Prevent Off Episodes in Adults with Parkinson's Disease
Nirosen Vijiaratnam et al.
DRUGS (2020)
A blinded, controlled trial of objective measurement in Parkinson's disease
Holly Woodrow et al.
NPJ PARKINSONS DISEASE (2020)
More Sensitive Identification for Bradykinesia Compared to Tremors in Parkinson's Disease Based on Parkinson's KinetiGraph (PKG)
Lina Chen et al.
FRONTIERS IN AGING NEUROSCIENCE (2020)
PKG Movement Recording System Use Shows Promise in Routine Clinical Care of Patients With Parkinson's Disease
Rajeshree Joshi et al.
FRONTIERS IN NEUROLOGY (2019)
Short- and Long-Term Cost and Utilization of Health Care Resources in Parkinson's Disease in the UK
Sharada Weir et al.
MOVEMENT DISORDERS (2018)
Levodopa Effect and Motor Function in Late Stage Parkinson's Disease
Kristina Rosqvist et al.
JOURNAL OF PARKINSONS DISEASE (2018)
Motor and Nonmotor Complications of Levodopa: Phenomenology, Risk Factors, and Imaging Features
K. Ray Chaudhuri et al.
MOVEMENT DISORDERS (2018)
Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
E. Ray Dorsey et al.
LANCET NEUROLOGY (2018)
The Emerging Evidence of the Parkinson Pandemic
E. Ray Dorsey et al.
JOURNAL OF PARKINSONS DISEASE (2018)
Progression of MDS-UPDRS Scores Over Five Years in De Novo Parkinson Disease from the Parkinson's Progression Markers Initiative Cohort
Samantha K. Holden et al.
MOVEMENT DISORDERS CLINICAL PRACTICE (2018)
Personalized Medicine in Parkinson's Disease: Time to Be Precise
Nataliya Titova et al.
MOVEMENT DISORDERS (2017)
Non-motor features of Parkinson disease
Anthony H. V. Schapira et al.
NATURE REVIEWS NEUROSCIENCE (2017)
GUIDELINES Parkinson's disease: summary of updated NICE guidance
Gabriel Rogers et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
GUIDELINES Parkinson's disease: summary of updated NICE guidance
Gabriel Rogers et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results
Tessa Kennedy-Martin et al.
TRIALS (2015)
Parkinson's disease and risk of mortality: meta-analysis and systematic review
J. Xu et al.
ACTA NEUROLOGICA SCANDINAVICA (2014)
Mapping the EQ-5D index by UPDRS and PDQ-8 in patients with Parkinson's disease
Judith Dams et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2013)
Patient Diaries As a Clinical Endpoint in Parkinson's Disease Clinical Trials
Spyridon (Spyros) Papapetropoulos
CNS NEUROSCIENCE & THERAPEUTICS (2012)
The Clinically Important Difference on the Unified Parkinson's Disease Rating Scale
Lisa M. Shulman et al.
ARCHIVES OF NEUROLOGY (2010)
Multi-state models for the analysis of time-to-event data
Luis Meira-Machado et al.
STATISTICAL METHODS IN MEDICAL RESEARCH (2009)
Parkinson's disease: clinical features and diagnosis
J. Jankovic
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2008)
Rate of clinical progression in Parkinson's disease. A prospective study
Anette Schrag et al.
MOVEMENT DISORDERS (2007)
Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030
E. R. Dorsey et al.
NEUROLOGY (2007)
Non-motor symptoms of Parkinson's disease: diagnosis and management
KR Chaudhuri et al.
LANCET NEUROLOGY (2006)
Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra
K Claxton et al.
HEALTH ECONOMICS (2005)
Share Paper
